Published in J Natl Cancer Inst on March 10, 2009
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Overdiagnosis and overtreatment of prostate cancer. Eur Urol (2014) 3.25
Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst (2014) 3.19
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med (2013) 1.84
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol (2012) 1.64
STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 1.63
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ (2015) 1.61
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer (2009) 1.59
Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst (2012) 1.50
A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer. Am J Epidemiol (2015) 1.48
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A (2014) 1.38
Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer (2013) 1.26
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Reduced risk of prostate cancer in U.S. Men with AIDS. Cancer Epidemiol Biomarkers Prev (2010) 1.23
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team. J Cancer Educ (2012) 1.22
Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One (2012) 1.21
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate (2012) 1.18
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Toward the detection of prostate cancer in urine: a critical analysis. J Urol (2012) 1.13
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med (2010) 1.09
The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther (2009) 1.09
Gleason grade progression is uncommon. Cancer Res (2013) 1.09
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol (2011) 1.07
Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem (2013) 1.05
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2013) 1.04
Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res (2012) 1.03
Computational modeling and multilevel cancer control interventions. J Natl Cancer Inst Monogr (2012) 1.02
Cancer/testis antigens and urological malignancies. Nat Rev Urol (2012) 1.01
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci (2012) 1.01
When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr (2014) 1.00
Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00
A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer Causes Control (2010) 0.99
Racial/ethnic differences in cancer risk after kidney transplantation. Am J Transplant (2013) 0.98
Much more medicine for the oldest old: trends in UK electronic clinical records. Age Ageing (2014) 0.98
Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. Int J Mol Med (2012) 0.98
Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med (2012) 0.98
The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer (2015) 0.98
Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making (2011) 0.96
Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? J Natl Cancer Inst (2009) 0.96
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A (2013) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med (2013) 0.93
Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol (2012) 0.92
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer (2013) 0.92
Screening for prostate cancer: early detection or overdetection? Annu Rev Med (2011) 0.92
Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions. J Natl Cancer Inst Monogr (2012) 0.91
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol (2014) 0.91
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate (2015) 0.90
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate (2011) 0.89
Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88
Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn (2014) 0.87
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor. Biosensors (Basel) (2012) 0.86
Early detection of prostate cancer: is screening in general practice justifiable? Scand J Prim Health Care (2011) 0.86
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Predicting disease progression from short biomarker series using expert advice algorithm. Sci Rep (2015) 0.84
Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. Ann Lab Med (2013) 0.83
Treatment options for localized prostate cancer. Can Fam Physician (2013) 0.83
Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.83
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
Retracted Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int (2013) 0.82
Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer (2012) 0.82
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer (2015) 0.82
Locus-specific gene repositioning in prostate cancer. Mol Biol Cell (2015) 0.82
Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006. Prev Chronic Dis (2011) 0.82
Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. J Natl Cancer Inst Monogr (2013) 0.82
Current status of active surveillance in prostate cancer. Investig Clin Urol (2016) 0.81
Developing a nanoparticle test for prostate cancer scoring. J Transl Med (2012) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer. J Oncol (2014) 0.80
Trends in prostate cancer incidence and mortality in Croatia, 1988-2008. Croat Med J (2012) 0.80
Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. J Natl Cancer Inst (2015) 0.80
Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate (2010) 0.80
Serum markers in prostate cancer detection. Curr Opin Urol (2015) 0.80
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics (1984) 4.73
Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA (1998) 4.19
Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol (1983) 4.11
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet (1994) 2.83
A population model of prostate cancer incidence. Stat Med (2006) 2.44
Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst (1999) 2.35
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst (1995) 1.96
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol (1994) 1.69
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer (2001) 1.59
How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol (1992) 1.59
Nonparametric estimation of the size-metastasis relationship in solid cancers. Biometrics (1991) 1.55
Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer (2002) 1.41
Combining longitudinal studies of PSA. Biostatistics (2004) 1.40
Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci (2001) 1.30
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol (2006) 1.24
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int (2000) 1.21
Modeling Disease Progression with Longitudinal Markers. J Am Stat Assoc (2008) 1.13
What is low-risk prostate cancer and what is its natural history? World J Urol (2008) 1.09
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology (1996) 1.01
MISCAN: estimating lead-time and over-detection by simulation. BJU Int (2003) 0.97
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Studies of prostate-cancer mortality: caution advised. Lancet Oncol (2008) 2.22
Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen (2012) 2.21
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer (2006) 1.89
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med (2013) 1.84
Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care (2009) 1.76
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ (2008) 1.72
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis (2013) 1.69
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. Radiology (2006) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer (2006) 1.60
Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst (2011) 1.58
Combining results of microarray experiments: a rank aggregation approach. Stat Appl Genet Mol Biol (2006) 1.56
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int (2011) 1.48
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41
The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Ann Intern Med (2016) 1.41
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
Combining longitudinal studies of PSA. Biostatistics (2004) 1.40
The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res (2004) 1.39
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. Anesthesiology (2013) 1.37
The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36
Cluster-based network model for time-course gene expression data. Biostatistics (2006) 1.35
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Burden of illness in adult survivors of childhood cancers: findings from a population-based national sample. Cancer (2010) 1.26
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
Comparison of tests for spatial heterogeneity on data with global clustering patterns and outliers. Int J Health Geogr (2009) 1.20
Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr (2010) 1.17
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.14
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13
Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res (2009) 1.13
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol (2010) 1.12
Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev (2010) 1.12
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol (2004) 1.09
Estimating the variance of cancer prevalence from population-based registries. Stat Methods Med Res (2006) 1.06
Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst (2014) 1.04
Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr (2006) 1.03
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03
Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer (2009) 1.02
Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. Cancer (2007) 1.02
Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. Anesthesiology (2015) 1.01
Comparison of SEER Treatment Data With Medicare Claims. Med Care (2016) 1.01
Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol (2015) 1.00
Differential expression and network inferences through functional data modeling. Biometrics (2008) 1.00
Estimating complete prevalence of cancers diagnosed in childhood. Stat Med (2008) 0.99
What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med (2010) 0.99
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs (2010) 0.97
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96
Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev (2003) 0.96
Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer (2002) 0.95
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Stage-specific cancer incidence: an artificially mixed multinomial logit model. Stat Med (2009) 0.95
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol (2012) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer (2005) 0.94